Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Non Small Cell Lung Cancer
Clinical trial register · France

Non Small Cell Lung Cancer Trials in France, 2026

Every study on the ClinicalTrials.gov registry that lists a site in France and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 9729 matching records held by the registry are in this view. Synced 14 Nov 2026, 03:18 UTC
9729
Studies in scope
all four open statuses
6052
Recruiting now
open to new participants
1030
Lead sponsors
across recruiting studies
Top sites
Paris 46 Marseille 45 Lyon 39 Bordeaux 32 Angers 28
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca13 Merck Sharp & Dohme LLC10 Eli Lilly and Company7 AbbVie5 Hoffmann-La Roche5 Bristol-Myers Squibb4 Intergroupe Francophone de Cancerologie Thoracique4 Pfizer4 ETOP IBCSG Partners Foundation3 Groupe Francais De Pneumo-Cancerologie3 Gilead Sciences3 Novartis Pharmaceuticals3 UNICANCER2 University Hospital, Brest2 Summit Therapeutics2 University Hospital, Bordeaux2 Centre Georges Francois Leclerc2 Pierre Fabre Medicament2 Daiichi Sankyo2 Dizal Pharmaceuticals2 European Organisation for Research and Treatment of Cancer - EORTC2 Verastem, Inc.2 Regeneron Pharmaceuticals2 Institut Bergonié2 GFPC Investigation2 Show all 56
Site location
Paris46 Marseille45 Lyon39 Bordeaux32 Angers28 Caen28 Villejuif27 Montpellier24 Lille23 Avignon21 Bron21 Brest19 Rennes19 Créteil18 Dijon18 Clermont-Ferrand15 Toulouse11 Saint-Herblain11 Nantes9 Le Mans9 Strasbourg9 La Tronche9 Suresnes9 Nice9 Bayonne8 Show all 84
All 84 locations
Target enrolment
to

Non Small Cell Lung Cancer trials in France

122 of 9729 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in France
Start
Recruiting
Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis
NCT07376512Non-Small Cell Lung Cancer, Melanoma (Skin Cancer)
Centre Georges Francois Leclerc
Observational
378
Besançon, Dijon, Lyon
2026-11-01
Not yet open
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2
158
Clermont-Ferrand, Lyon, Nice, Reims, Villejuif
2026-11
Recruiting
Centre Leon Berard
Not applicable
40
Lyon, Villefranche-sur-Saône
2026-10-29
Recruiting
Hoffmann-La Roche
Phase 3
400
Avignon, Quimper, Reims, Suresnes
2026-10-06
Recruiting
Bristol-Myers Squibb
Phase 3
850
Marseille, Dijon, Nantes, La Tronche, Lyon, Paris, Bron, Villejuif
2026-09-08
Recruiting
Centre Georges Francois Leclerc
Phase 1/2
24
Dijon
2026-07-07
Recruiting
Merck Sharp & Dohme LLC
Phase 3
310
Pessac, Valenciennes
2026-06-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
876
Rennes, Suresnes, Clermont-Ferrand
2026-05-04
Recruiting
Central Hospital, Nancy, France
Observational
70
Nancy
2026-04-03
Recruiting
Merck Sharp & Dohme LLC
Phase 3
400
Marseille, Caen, Montpellier, Créteil
2026-03-18
Recruiting
Institut Paoli-Calmettes
Not applicable
200
Marseille
2026-02-12
Recruiting
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
DrugsSigvotatug vedotin·PF-08634404
Pfizer
Phase 1/2
162
Bordeaux, Dijon, Marseille, Paris
2026-01-30
Recruiting
Boehringer Ingelheim
Phase 3
400
Bron, Marseille, Nantes, Paris, Rennes, Strasbourg, Toulouse, Villejuif
2026-01-16
Recruiting
ETOP IBCSG Partners Foundation
Phase 3
390
Angers, Avignon
2026-01-12
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Limoges, Angers, Paris, Vandœuvre-lès-Nancy, Villejuif, Boulogne-Billancourt
2026-01-06
Recruiting
University Hospital, Angers
Observational
75
Angers, Le Mans
2025-12-17
Recruiting
ArriVent BioPharma, Inc.
Phase 3
480
Bron, Marseille, Caen, Toulouse, Lyon, Saint-Herblain
2025-12-17
Recruiting
AbbVie
Phase 2/3
490
Marseille, Brest, Lille, Montpellier, Paris
2025-12-10
Not yet open
University Hospital, Strasbourg, France
Observational
50
Strasbourg
2025-12-01
Not yet open
Effect of G-CSF on MDSC and Cancer Stem-cells Interactions in Non-small Cell Lung Cancers (CIRCUIT)
NCT06711770Non Small Cell Lung Cancer, Immunotherapy, Granulocyte Colony Stimulating Factor
DrugBlood sample
University Hospital, Bordeaux
Not applicable
30
Bordeaux
2025-12
Recruiting
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
NCT07261631Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
Drug68Ga-NNS309
Novartis Pharmaceuticals
Phase 1
180
Vandœuvre-lès-Nancy
2025-11-24
Recruiting
Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer
NCT07563205Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer NSCLC, Non Small Cell Lung Carcinoma
GFPC Investigation
Observational
100
Aix-en-Provence, Bobigny, Bron, Caen, Créteil, Le Chesnay, Lille, Lyon
2025-11-19
Recruiting
Bristol-Myers Squibb
Phase 2/3
661
Strasbourg, Toulouse, Lille, La Tronche, Saint-Herblain, Bron, Villejuif, Marseille
2025-11-05
Recruiting
UNICANCER
Phase 2
105
Angers, Marseille, Vandœuvre-lès-Nancy, Villejuif
2025-10-30
Recruiting
Daiichi Sankyo
Phase 3
686
Angers, Bordeaux, Boulogne-Billancourt, Bron, Créteil, Dijon, Lille, Lyon
2025-10-24
Recruiting
Hoffmann-La Roche
Phase 3
600
Angers, Bobigny, Bron, Caen, Lyon, Montpellier, Nice, Paris
2025-10-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Marseille, Caen, Vandœuvre-lès-Nancy, Pau, Chambéry, Amiens, Paris
2025-10-08
Active, closed
Bristol-Myers Squibb
Phase 2
76
Dijon, Suresnes, Paris
2025-09-19
Recruiting
Wayshine Biopharm, Inc.
Phase 2
40
Rennes, Limoges, Pessac, Caen, Toulon
2025-08-18
Recruiting
AstraZeneca
Phase 2
278
Avignon, Paris, Rennes, Saint-Herblain, Suresnes
2025-08-07
Recruiting
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
NCT07094204Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
DrugPanitumumab
Astellas Pharma Inc
Phase 1
404
Bordeaux, Lyon, Pierre-Bénite, Villejuif
2025-07-25
Recruiting
Pfizer
Phase 3
714
Pessac, Quimper, Toulouse, Rennes, Montpellier, Saint-Herblain, Cholet, Toulon
2025-07-23
Active, closed
BicycleTx Limited
Phase 2
73
Paris
2025-07-18
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
DrugsNeladalkib·Alectinib
Nuvalent Inc.
Phase 3
450
Angers, Bordeaux, Caen, Lyon, Marseille, Montpellier, Nantes, Paris
2025-07-17
Recruiting
Assistance Publique - Hôpitaux de Paris
Not applicable
385
Créteil
2025-07-09
Not yet open
University Hospital, Montpellier
Observational
72
Montpellier
2025-07-01
Recruiting
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
NCT07020221Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult
DrugsVS-7375·Repaglinide·Defactinib·Erbitux
Verastem, Inc.
Phase 1/2
616
Lyon, Marseille, Paris
2025-06-24
Recruiting
Hybrid Prehabilitation Before Thoracic Surgery
NCT06866717Non-Small Cell Lung Cancer
ADIR Association
Not applicable
38
Rouen
2025-05-30
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
DrugsCetuximab·Docetaxel
Revolution Medicines, Inc.
Phase 3
590
Strasbourg, Marseille, Montpellier, Rennes, La Tronche, Saint-Herblain, Léon, Lille
2025-05-06
Recruiting
Summit Therapeutics
Phase 3
780
Nantes, Avignon, Brest, Créteil, Lille, Lyon, Marseille, Paris
2025-02-27
Not yet open
University Hospital, Brest
Observational
120
Brest, Morlaix
2025-01-30
Recruiting
ETOP IBCSG Partners Foundation
Phase 3
290
Angers, Bordeaux, Le Mans, Lyon
2025-01-15
Recruiting
BioNTech SE
Phase 2/3
1,580
Angers, Bayonne, Bordeaux, Bron, Caen, Clermont-Ferrand, Créteil, La Tronche
2025-01-07
Active, closed
Brain Oligometastasis in NSCLC
NCT07389642Brain Oligometastatic, Non-small Cell Lung Cancer
University Hospital, Bordeaux
Observational
46
Bordeaux
2025-01-01
Active, closed
Regeneron Pharmaceuticals
Phase 2
184
Rennes, Toulon, Bayonne, Grenoble, Montpellier, Paris
2024-11-18
Recruiting
AstraZeneca
Phase 3
1,160
Avignon, La Rochelle, Lyon, Nîmes, Rennes, Strasbourg, Suresnes, Toulon
2024-11-18
Active, closed
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
Drugs5Fluorouracil·Leucovorin·Irinotecan·Cetuximab
Eli Lilly and Company
Phase 1
750
Lyon
2024-10-21
Recruiting
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT06562192Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
Novartis Pharmaceuticals
Phase 1
162
Bron, Villejuif
2024-10-15
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Dijon, Brest, Toulouse, Montpellier, Rennes, Vandœuvre-lès-Nancy, Lille, Le Mans
2024-10-07
Recruiting
GFPC Investigation
Phase 4
500
Aix-en-Provence, Avignon, Bastia, Brest, Caen, Chambéry, Cherbourg, Clermont-Ferrand
2024-09-26
Active, closed
Hoffmann-La Roche
Phase 3
338
Brest, Bron, Lille, Lyon, Montpellier, Nice, Paris, Pessac
2024-09-23
Active, closed
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
NCT06561685Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
DrugsNab-paclitaxel·Pemetrexed·Paclitaxel·Cisplatin
Eli Lilly and Company
Phase 1
340
Bordeaux, Paris, Villejuif
2024-09-19
Active, closed
Amgen
Phase 1
49
Bordeaux, Marseille, Saint-Herblain, Villejuif
2024-09-17
Active, closed
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
DrugsLeucovorin·Irinotecan·Cetuximab·Adrucil
Eli Lilly and Company
Phase 1
630
Lyon, Marseille, Toulouse, Villejuif
2024-09-12
Active, closed
AstraZeneca
Phase 2
194
Bois-Guillaume, Caen, Dijon, Montpellier
2024-08-27
Recruiting
University Hospital, Lille
Phase 1/2
21
Lille
2024-07-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Marseille, Vantoux, Angers, Avignon, La Roche-sur-Yon, Paris
2024-06-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
348
Nice, Dijon, Quimper, Nîmes, Valenciennes, Clermont-Ferrand, Avignon, Boulogne-Billancourt
2024-05-24
Recruiting
AstraZeneca
Phase 3
582
Angers, Marseille, Paris, Strasbourg
2024-04-29
Active, closed
AbbVie
Phase 2/3
167
Marseille, La Tronche, Paris, Bron, Créteil
2024-04-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Brest, Toulouse, Rouen, Limoges, Valenciennes, Clermont-Ferrand, Bron, Toulon
2024-04-03
Active, closed
AstraZeneca
Phase 2
142
La Tronche, Marseille, Montpellier, Mulhouse, Paris, Pessac, Poitiers, Toulouse
2024-02-22
Recruiting
Intergroupe Francophone de Cancerologie Thoracique
Not applicable
300
Angers, Bayonne, Boulogne, Bron, Caen, Clermont-Ferrand, Colmar, Créteil
2024-01-22
Recruiting
Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion
NCT06247826Non-small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation
Groupe Francais De Pneumo-Cancerologie
Not applicable
30
Bordeaux, Brest, Créteil, Dijon, Grenoble, Le Mans, Marseille, Nice
2024-01-15
Active, closed
Merck Sharp & Dohme LLC
Phase 2
147
Lyon Cedex08, Caen, Limoges, Toulon, Paris
2023-12-26
Active, closed
Merck Sharp & Dohme LLC
Phase 3
868
Strasbourg, Pessac, Marseille, Caen, Montpellier, Angers, Clermont-Ferrand, Paris
2023-12-06
Active, closed
Summit Therapeutics
Phase 3
1,600
Brest, Caen, Créteil, Le Mans, Marseille, Montpellier, Paris, Pierre-Bénite
2023-10-26
Recruiting
Pierre Fabre Medicament
Phase 1/2
345
Saint-Herblain, Bordeaux, Lille, Lyon, Marseille, Toulouse, Villejuif
2023-09-26
Recruiting
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
NCT05983432Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer
DrugIza-bren
SystImmune Inc.
Phase 1
540
Lyon, Paris, Saint-Herblain, Villejuif
2023-08-08
Recruiting
Innate Pharma
Phase 2
70
Angers, Caen, Lille, Limoges, Lyon, Marseille, Rennes, Rouen
2023-06-23
Active, closed
Intergroupe Francophone de Cancerologie Thoracique
Phase 2
156
Amiens, Angers, Avignon, Bayonne, Besançon, Bordeaux, Boulogne, Caen
2023-04-26
Recruiting
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NCT05786924Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation
DrugsPanitumumab·Folfox·Cetuximab·Nab-paclitaxel
Institut de Recherches Internationales Servier
Phase 1/2
554
Dijon, Paris, Rennes, Villejuif
2023-04-18
Active, closed
ETOP IBCSG Partners Foundation
Phase 2
60
Angers, Avignon, Lyon
2023-03-27
Recruiting
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours
NCT05752552Adult Solid Tumor, Advanced Solid Tumor, Refractory Tumor, Non-small Cell Lung Cancer
DeuterOncology
Phase 1
55
Bordeaux, Lille, Lyon, Marseille, Nice, Rennes, Villejuif
2022-12-20
Active, closed
Dizal Pharmaceuticals
Phase 3
324
Angers, Bron, Créteil, Hellemmes-Lille, La Tronche, Marseille, Montpellier, Paris
2022-12-13
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
40
Lyon, Marseille, Paris, Villejuif
2022-12-13
Active, closed
Hoffmann-La Roche
Phase 3
68
Caen, Lyon, Marseille
2022-11-01
Active, closed
Regeneron Pharmaceuticals
Observational
509
Mulhouse, Strasbourg, Marseille, Avignon, Poitiers, Angers, Clermont-Ferrand, Le Mans
2022-10-26
Active, closed
Gilead Sciences
Phase 3
1,021
Boulogne-Billancourt, Le Mans, Marseille, Montpellier, Saint-Herblain, Saint-Mandé, Saint-Quentin, Suresnes
2022-10-12
Active, closed
Gilead Sciences
Phase 2
193
Boulogne-Billancourt, Brest, Caen, Clermont-Ferrand, Dijon, Le Mans, Paris, Pessac
2022-05-30
Active, closed
Intergroupe Francophone de Cancerologie Thoracique
Phase 2
110
Angers, Besançon, Boulogne, Bron, Caen, Clermont-Ferrand, Créteil, Dijon
2022-05-18
Recruiting
AstraZeneca
Phase 2
630
Avignon, Bobigny, Bordeaux, Limoges, Rennes, Rouen, Suresnes, Toulon
2022-04-14
Active, closed
Verastem, Inc.
Phase 1/2
153
Lille, Paris, Suresnes
2022-04-12
Recruiting
AbbVie
Phase 3
768
Marseille, Lille, Montpellier, Pessac, Paris, Avignon, Bron, Lyon
2022-03-25
Active, closed
AstraZeneca
Phase 3
791
Aix-en-Provence, Angers, Bobigny, Lille, Paris, Pau, Quimper, Saint-Grégoire
2022-02-18
Active, closed
AstraZeneca
Phase 3
1,051
Avignon, Besançon, Bordeaux, Clermont-Ferrand, Créteil, Lorient, Marseille, Montpellier
2022-02-07
Active, closed
Lorlatinib Continuation Study
NCT05144997Non-Small-Cell Lung Cancer, NSCLC
DrugLorlatinib
Pfizer
Phase 4
76
Rennes, Villejuif
2021-12-28
Active, closed
Gilead Sciences
Phase 3
603
Avignon, Bayonne, Boulogne-Billancourt, Caen, Calvados, Chauny, Clermont-Ferrand, Créteil
2021-11-17
Active, closed
AbbVie
Phase 1
520
Bordeaux, Saint-Herblain, Nice, Lyon, Villejuif, Dijon, Paris
2021-10-13
Recruiting
Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC
NCT05122806Non-small Cell Lung Cancer, ALK Gene Rearrangement Positive
Groupe Francais De Pneumo-Cancerologie
Not applicable
100
Saint-Denis, Aix-en-Provence, Amiens, Angers, Annecy, Brest, Caen, Chambéry
2021-09-22
Recruiting
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT05059444Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer
Guardant Health, Inc.
Observational
2,285
Besançon, Levallois-Perret, Marseille, Neuilly, Paris
2021-09-07
Active, closed
Nuvation Bio Inc.
Phase 2
217
Bron, La Tronche, Lyon 08, Marseille, Paris, Poitiers, Reims, Rennes
2021-09-01
Recruiting
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
NCT04913285Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
Pierre Fabre Medicament
Phase 1
400
Bordeaux, Caen, Lille, Lyon, Marseille, Nantes, Nice, Paris
2021-08-04
Recruiting
Boehringer Ingelheim
Phase 1
554
Bron, Lyon, Marseille, Paris, Rennes, Villejuif
2021-07-02
Active, closed
AstraZeneca
Observational
274
Abbeville, Aix-en-Provence, Angers, Antibes, Avignon, Bastia, Bayonne, Bordeaux
2021-05-12
Active, closed
Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors
NCT03915678Solid Tumor, Adult, Pancreatic Cancer, Virus-associated Tumors, Non Small Cell Lung Cancer
Institut Bergonié
Phase 2
247
Bordeaux, Brest, Caen, Dijon, Lille, Marseille, Paris, Poitiers
2021-03-31
Active, closed
ENCOrafenib With Binimetinib in bRAF NSCLC
NCT04526782Non Small Cell Lung Cancer, BRAF V600E
DrugsEncorafenib·Binimetinib
Intergroupe Francophone de Cancerologie Thoracique
Phase 2
119
Ambilly, Angers, Avignon, Bordeaux, Boulogne-Billancourt, Brest, Caen, Colmar
2021-01-19
Active, closed
University Hospital, Brest
Phase 3
349
Aix-en-Provence, Amiens, Angers, Brest, Caen, Chambéry, Créteil, La Roche-sur-Yon
2020-12-22
Active, closed
Daiichi Sankyo
Phase 3
605
Besançon, Grenoble, Lyon, Marseille, Nantes, Paris, Poitiers, Rennes
2020-12-21
Active, closed
Groupe Francais De Pneumo-Cancerologie
Observational
413
Aix-en-Provence, Amiens, Angers, Annecy, Brest, Chambéry, Champigny-sur-Marne, Chauny
2020-12-18
Active, closed
AstraZeneca
Phase 3
358
Avignon, Bordeaux
2020-12-16
Active, closed
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2
68
Avignon, Bobigny, Brest, Créteil, Villejuif
2020-11-17
Active, closed
Razor Genomics
Not applicable
420
Bordeaux, Rouen, Angers, Bayonne, Besançon, Boulogne, Clamart, Créteil
2020-09-11
Active, closed
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
NCT04258137Colorectal Cancer, Non Small Cell Lung Cancer
Institut Bergonié
Not applicable
332
Bayonne, Bordeaux, Brest, Pau
2020-09-04
Active, closed
Eli Lilly and Company
Phase 3
261
Lyon, Marseille, Montpellier, La Tronche, Clermont-Ferrand, Paris
2020-02-17
Active, closed
PDC*line Pharma SAS
Phase 1/2
73
Grenoble, Lyon, Nantes
2019-09-10
Active, closed
Dizal Pharmaceuticals
Phase 1/2
315
Angers, Bron, Dijon, Hellemmes-Lille, Marseille, Montpellier, Paris, Poitiers
2019-07-09
Active, closed
AstraZeneca
Phase 3
587
Bordeaux, Lyon, Montpellier, Villejuif
2019-07-02
Active, closed
AstraZeneca
Phase 3
825
Avignon, Lyon, Nice, Toulon, Vantoux
2018-12-06
Active, closed
AbbVie
Phase 2
270
Marseille, Bordeaux, Lille, Paris, Bron, Lyon, Créteil, Villejuif
2018-10-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
797
Suresnes, Pierre-Bénite, Strasbourg, Toulouse, Limoges, Chambéry, Pringy, Rouen
2018-04-24
Recruiting
Dabrafenib and/or Trametinib Rollover Study
NCT03340506Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
100
Lyon, Nantes, Paris, Villejuif
2018-01-26
Active, closed
PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer
NCT03774732Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4
DrugPembrolizumab
UNICANCER
Phase 3
327
Angers, Arras, Avignon, Beuvry, Blois, Bordeaux, Brest, Caen
2018-01-24
Active, closed
AstraZeneca
Phase 2
528
Bordeaux, Nantes, Paris, Villejuif
2017-12-18
Active, closed
Hoffmann-La Roche
Phase 2/3
1,000
Bordeaux, Caen, Lille, Lyon, Nîmes, Nouilly, Paris, Poitiers
2017-09-22
Active, closed
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03170960Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer
DrugsCabozantinib·Tecentriq·Atezolizumab
Exelixis
Phase 1
914
La Roche-sur-Yon, Villejuif, Bordeaux, Brest, Caen, Le Mans, Lille, Lyon
2017-09-05
Active, closed
Microbiota and the Lung Cancer
NCT03068663Non Small Cell Lung Cancer
Centre Jean Perrin
Not applicable
40
Clermont-Ferrand
2017-05-23
Active, closed
Eli Lilly and Company
Phase 1/2
857
Bordeaux, Lyon, Marseille, Montpellier, Villejuif, Paris
2017-05-02
Active, closed
Eli Lilly and Company
Phase 1
100
Lille, Montpellier, Toulouse
2016-11-14
Active, closed
Xcovery Holdings, Inc.
Phase 3
290
Lille, Montpellier, Rennes, Vellefaux
2016-06
Active, closed
Janssen Research & Development, LLC
Phase 1
751
Bordeaux, Dijon, Lyon, Marseille, Paris, Saint-Herblain, Villejuif
2016-05-24
Active, closed
Eli Lilly and Company
Phase 3
453
Bron, Dijon, Grenoble, Lille, Marseille, Poitiers, Rennes, Saint-Brieuc
2014-10-03
Rows per page Showing 1–122 of 122
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a French investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 14 November 2026. https://priyalifescience.com/clinical-trials-france/condition/non-small-cell-lung-cancer

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in France and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,729 studies in total at the last sync on 14 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 122 of those studies listing the condition Non Small Cell Lung Cancer.

How many Non Small Cell Lung Cancer trials are recruiting in France?

60 of the 122 studies on this page are recruiting new participants as of the 14 Nov 2026, 03:18 UTC sync. A further 5 have not yet opened recruitment, 57 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Non Small Cell Lung Cancer), 122 studies
PhaseStudiesRecruitingShare
Phase 3432435.2%
Phase 223618.9%
Phase 115712.3%
Observational1259.8%
Not applicable1179%
Phase 1/21068.2%
Phase 2/3534.1%
Phase 4322.5%

Most active sponsors

Lead sponsors with the most studies (Non Small Cell Lung Cancer)
Lead sponsorStudiesRecruiting
AstraZeneca134
Merck Sharp & Dohme LLC107
Eli Lilly and Company70
AbbVie52
Hoffmann-La Roche52
Bristol-Myers Squibb43
Intergroupe Francophone de Cancerologie Thoracique41
Pfizer43
ETOP IBCSG Partners Foundation32
Gilead Sciences30
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.